John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive


Immune checkpoint inhibitors-induced hepatitis: Not so rare. Liver biopsy is useful to diagnostic and therapeutic management Volume 26, issue 2, Février 2019

  • [1] Tursz T. La nouvelle immunothérapie des cancers : le réveil de la belle au bois dormant ? Innov Ther Oncol 2017 ; 3 : 115-20.
  • [2] Olive D., Golstein P. CTLA-4 et PD-1 : des origines aux anticorps. Innov Ther Oncol. 2017;3:121-130.
  • [3] Postow M.A., Sidlow R., Hellmann M.D. Immune-related adverse effects with immune checkpoint blockade. N Engl J Med. 2018;378:158-168.
  • [4] Khoja L., Day D., Wei-Wu Chen, Siu L.L., Hansen A.R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoints inhibitors: a systematic review. Ann Oncol. 2017;28:2377-2385.
  • [5] Bhave P., Bückle A., Sandhu S., Sood S. Mortality due to immunotherapy related hepatitis. J Hepatol. 2018;69:976-978.
  • [6] Wang D.I., Salem J.-E., Cohen J.V. Fatal toxic effects associated with immune checkpoints inhibitors. A systematic review and meta-analysis. JAMA Oncol. 2018;4:1721-1728. 12
  • [7] Riveiro-Barciela M, Muñoz-Couselo E, Fernadez-Sojo J, Diaz-Mejia N, Parra-Lopez R, Buti M. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies ? J Hepatol. 2018 Nov 28. pii: S0168-8278(18)32504-2. Doi : 10.1016/j.jhep.2018.10.020.[Epub ahead of print].
  • [8] De Martin E., Michot J.-M., Papouin B. Reply to « Incidence of grade 3-4 liver injury under immune checkpoint inhibitors : a retrospective study ». J Hepatol. 2018;69:1396-1401.
  • [9] Soularue E., Lepage P., Colombel J.F. Enterocolitis due to immune checkpoint inhibitors : a systematic review. Gut. 2018;67:2056-2057.